TY - JOUR
T1 - The Role of Probiotics, Prebiotics and Synbiotics in Combating Multidrug-Resistant Organisms
AU - Newman, Alexander M.
AU - Arshad, Mehreen
N1 - Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/9
Y1 - 2020/9
N2 - The prevalence of multidrug-resistant organisms is increasing worldwide, posing a unique challenge to global health care systems. Novel approaches are needed to combat the spread of infection with these organisms. The enteric microbiome, and in particular the resistome, offers a unique target in both the prevention of infection with these organisms and the acquisition and spread within the community. We highlight a novel approach to combat multidrug-resistant organisms: the use of prebiotics, probiotics, and synbiotics to manipulate the microbiome and resistome. This review summarizes the published literature and clinical trials related to these products to date, with a focus on efficacious trials. It highlights the probable mechanism of action for each product, as well as its safety profile in selective populations. Ultimately, although further research is needed before a definitive statement can be made on the efficacy of any of these 3 interventions, the literature to date offers new hope and a new tool in the arsenal in the fight against bacterial drug resistance.
AB - The prevalence of multidrug-resistant organisms is increasing worldwide, posing a unique challenge to global health care systems. Novel approaches are needed to combat the spread of infection with these organisms. The enteric microbiome, and in particular the resistome, offers a unique target in both the prevention of infection with these organisms and the acquisition and spread within the community. We highlight a novel approach to combat multidrug-resistant organisms: the use of prebiotics, probiotics, and synbiotics to manipulate the microbiome and resistome. This review summarizes the published literature and clinical trials related to these products to date, with a focus on efficacious trials. It highlights the probable mechanism of action for each product, as well as its safety profile in selective populations. Ultimately, although further research is needed before a definitive statement can be made on the efficacy of any of these 3 interventions, the literature to date offers new hope and a new tool in the arsenal in the fight against bacterial drug resistance.
KW - microbiome
KW - multidrug-resistant organisms
KW - prebiotic
KW - probiotic
KW - resistome
KW - synbiotic
UR - http://www.scopus.com/inward/record.url?scp=85089381423&partnerID=8YFLogxK
U2 - 10.1016/j.clinthera.2020.06.011
DO - 10.1016/j.clinthera.2020.06.011
M3 - Review article
C2 - 32800382
AN - SCOPUS:85089381423
SN - 0149-2918
VL - 42
SP - 1637
EP - 1648
JO - Clinical Therapeutics
JF - Clinical Therapeutics
IS - 9
ER -